ICON Recognised for Leadership Position in Clinical Research Industry and as Socially Responsible Employer
10 Luglio 2024 - 1:15PM
Business Wire
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence
and clinical research organisation, has been honoured in the first
half of 2024 with a number of leading business and industry awards
recognising the company’s leadership position in the clinical
research industry, in addition to its efforts in inclusion,
sustainability and as an employer of choice.
At the CRO Leadership Awards 2024, ICON was recognised for its
excellence in clinical research in all categories. The awards are
based on direct feedback from sponsors that CROs have worked with
over the last 18 months. ICON also received Individual Attribute
Awards in the areas of data quality, meeting project timelines,
operational excellence, technology for access to data, and
therapeutic expertise.
ICON was also recognised for its technology solutions at the
Citeline 2024 awards, which showcase excellence in clinical trial
design and technological advancements. ICON’s AI solution,
Cassandra, won for Excellence in Use of Real-World Data/Evidence.
Citeline judges praised Cassandra as an “innovative and pragmatic
system to help trial sponsors predict future post-marketing
regulatory requirements and develop strategies to mitigate or
eliminate those requirements early-on in their programs”.
The company was named Clinical Research Company of the Year at
the PharmaTimes International Clinical Researcher of the Year
awards. The awards are designed to challenge, recognise and reward
the talent and passion of industry and academic researchers.
Overall, ICON boasted over 50 employees who received gold, silver
and bronze awards or who were nominated as finalists.
ICON’s site network, Accellacare, was named Best Clinical Trial
Network at the 2024 Vaccine Industry Excellence Awards. These
awards recognise outstanding efforts and positive contributions of
organisations and individuals in the vaccine industry.
Recently acquired by ICON, HumanFirst, a company that enables
better selection and integration of digital health technologies in
clinical trials, was named Best Clinical Trial Technology Solution
Provider at the 2024 MedTech Breakthrough Awards. These awards
recognise the top companies, people, platforms and products in the
health, fitness and medtech industries.
ICON's Creative & Digital Services and Global Medical
Communications teams were winners of a 2024 Viddy Award. They
received a Gold Award in the Non-Broadcast Short Form Web Videos
category.
Acknowledging the progress the company has made through its ICON
Cares program, the company was named the Social & Equality
Business of the Year at the 2024 PwC Business Post Sustainable
Business Awards. ICON was one of a record number of 150+ applicants
to the awards, which are a benchmark for excellence in ESG-related
business practices. Furthermore, ICON was included as one of
Europe’s Climate Leaders in 2024, as compiled by the Financial
Times in partnership with data provider Statista. The list
comprises European companies that achieved the greatest reduction
in their core emissions intensity between 2017 and 2022 and
fulfilled further climate-related criteria including transparency
of reporting, reduction of absolute emissions and further
collaborations and commitments.
In recognition of its foundation and impact in Ireland, ICON was
named as one of the best workplaces to grow your career in the
country, featuring on LinkedIn’s Top Companies list. This year’s 20
honourees have all invested in attracting and retaining employees
in a competitive Irish market.
Steve Cutler, CEO, ICON commented: “These awards are a testament
to the hard work, dedication and innovation of every employee at
ICON. I am proud of our achievements, which reinforce our
commitment to delivering value to our customers and our people and
driving the future of clinical research.”
A full list of ICON’s industry awards can be viewed at
www.iconplc.com/awards.
About ICON plc
ICON plc is a world-leading healthcare intelligence and clinical
research organisation. From molecule to medicine, we advance
clinical research providing outsourced services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. We develop new innovations, drive emerging therapies
forward and improve patient lives. With headquarters in Dublin,
Ireland, ICON employed approximately 41,150 employees in 102
locations in 54 countries as at March 31, 2024. For further
information about ICON, visit: www.iconplc.com.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240710959169/en/
Claire Quinn (GMT time zone) Corporate Communications, ICON plc
claire.quinn@iconplc.com +353 87 4066091 Weber Shandwick (PR
adviser) Lisa Henry (GMT time zone) +447785 458203
lhenry@webershandwick.com
Grafico Azioni ICON (NASDAQ:ICLR)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni ICON (NASDAQ:ICLR)
Storico
Da Gen 2024 a Gen 2025